Zumbro Discovery is a technology company.
Zumbro Discovery has raised $1.0M across 1 funding round.
Zumbro Discovery has raised $1.0M in total across 1 funding round.
Zumbro Discovery is a clinical-stage biotechnology company developing novel treatments for resistant hypertension, a condition affecting millions worldwide that resists standard therapies and contributes to heart failure and other cardiovascular issues.[3][5] The company builds ZD100, a patent-protected mutant atrial natriuretic peptide (MANP) derived from decades of research, targeting heart, kidney, and adrenal gland dysfunction to provide superior blood pressure control, natriuresis, and aldosterone suppression compared to native ANP.[5] It serves patients with resistant hypertension—who lack approved drug options—and healthcare providers seeking life-saving interventions, addressing a critical unmet need in cardiovascular medicine.[5]
Backed by investors like Broadview Ventures and Mayo Clinic Ventures, Zumbro has raised at least $1 million and advanced toward human clinical trials, positioning it for growth in the biotech sector focused on cardiorenal diseases.[2][4][5]
Zumbro Discovery was founded by cardiologists John Burnett MD and Horng Chen MD, who lead the Cardiorenal Research Laboratory at Mayo Clinic in Rochester, Minnesota.[2][5] Their idea emerged from decades of research on atrial natriuretic peptides (ANPs), culminating in the development of ZD100, a 40-amino-acid engineered peptide with enhanced therapeutic properties.[5]
The company gained early traction through the Mayo Clinic Business Accelerator as a founding tenant and secured $1 million in seed funding from Broadview Ventures in 2014, with plans to initiate human clinical trials that year—building on a favorable landscape after a failed Medtronic trial highlighted gaps in hypertension treatments.[3][4]
Zumbro Discovery rides the wave of precision cardiovascular biotech, capitalizing on advances in peptide engineering amid rising global hypertension burdens—exacerbated by aging populations and lifestyle factors.[3][5] Timing aligns with regulatory emphasis on cardiorenal syndromes and investor interest in novel therapies post-failures of device-based approaches like Medtronic's, creating space for biologic innovations.[4]
Market forces favor Zumbro: no approved drugs for resistant hypertension leaves a massive gap, while Mayo Clinic's ecosystem accelerates translation from lab to clinic.[3][5] It influences the ecosystem by validating ANP mutants as a platform, potentially inspiring follow-on therapies in heart-kidney-adrenal disorders and strengthening Rochester's biotech hub via the Mayo Accelerator.[2][3]
Zumbro Discovery stands poised for milestone advancements, likely advancing ZD100 through clinical trials to address a therapy void in resistant hypertension.[4][5] Trends like AI-driven peptide design and combo therapies for cardiorenal disease will shape its path, amplifying efficacy and market reach.
Its influence may expand via partnerships or acquisitions by big pharma seeking cardiovascular pipelines, evolving from Mayo spinout to category leader—ultimately delivering the first approved treatment where none exists, fulfilling its promise as a biotechnology pioneer.[5]
Zumbro Discovery has raised $1.0M in total across 1 funding round.
Zumbro Discovery's investors include Broadview Ventures.
Zumbro Discovery has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Series A in March 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2013 | $1.0M Series A | Broadview Ventures |